← Human Trials & Peer-Reviewed Studies
Acadesine inhibits neutrophil CD11b up-regulation in vitro and during in vivo cardiopulmonary bypass
Plain-language guide to PMID 7877305 (1995): placebo-controlled randomized controlled trial study of AICAR in 34 patients.
Key Facts
- PMID
- 7877305
- Journal
- The Journal of thoracic and cardiovascular surgery
- Year
- 1995
- Study type
- Randomized Controlled Trial
- Authors
- Mathew JP et al. (7 authors)
- DOI
- 10.1016/S0022-5223(95)70275-X
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at AICAR.
The purpose of this study was to measure changes in granulocyte CD11b/CD18 in an in vitro assay and in an in vivo trial of acadesine administered during cardiopulmonary bypass to determine whether this agent might modulate up-regulation of this adhesion receptor.
Why It Was Studied
Granulocyte adhesion to ischemic tissue, mediated in large part by beta 2 integrin receptors, is important in the pathophysiology of reperfusion injury.
In vitro, whole blood was incubated with acadesine or control diluent, stimulated with N-formyl-methionyl-leucyl-phenylalanine, and granulocyte CD11b measured.
Who Took Part
The study group was 34 patients.
By PubMed's age tags, the people studied were middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, placebo-controlled and multicenter study.
The patients were allocated by chance, so the AICAR group and the comparison group should start out alike.
The comparison arm used a placebo, so changes seen with AICAR could be set against what happens without it.
Running at several centres spread the AICAR study over different clinics and patient groups.
What Was Measured
In vitro, whole blood was incubated with acadesine or control diluent, stimulated with N-formyl-methionyl-leucyl-phenylalanine, and granulocyte CD11b measured.
PubMed files the paper under topics including Adenosine, Aminoimidazole Carboxamide, CD18 Antigens, Cardiopulmonary Bypass, Macrophage-1 Antigen, N-Formylmethionine Leucyl-Phenylalanine and Neutrophils.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and multicenter study of AICAR in 34 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1995 (The Journal of thoracic and cardiovascular surgery), a journal based in United States.
More context: the AICAR compound page, all human trials.
Our Notes on the Compound
AICAR: A research compound that activates AMPK, nicknamed the “exercise pill”; prohibited in sport and not approved for human use.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.